Bristol-Myers Squibb: Losing Otezla Might Be Challenging

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 25, 2019 at 9:52 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,741
    Likes Received:
    3
    via The probable divestiture of Otezla raises concerns about the pricing of the Bristol-Myers Squibb and Celgene deal. The drug is one of Celgene’s major commercialized assets. Investors are concerned about the valuation that Otezla will secure in the divestiture considering Bristol-Myers Squibb’s urgency to complete the transaction.

    article source